 Mary Bessesen
Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 8 | 2024 | 380 | 2.610 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 7 | 2024 | 212 | 2.470 |
Why?
| | Respiratory Protective Devices | 6 | 2021 | 12 | 2.440 |
Why?
| | Nasal Cavity | 5 | 2024 | 51 | 2.110 |
Why?
| | Carrier State | 5 | 2024 | 60 | 2.100 |
Why?
| | Intraabdominal Infections | 8 | 2024 | 11 | 1.870 |
Why?
| | Bacteremia | 6 | 2020 | 194 | 1.530 |
Why?
| | Infection Control | 8 | 2023 | 134 | 1.490 |
Why?
| | Nose | 3 | 2024 | 64 | 1.480 |
Why?
| | Cross Infection | 7 | 2023 | 196 | 1.470 |
Why?
| | Health Personnel | 10 | 2021 | 649 | 1.390 |
Why?
| | Respiratory Tract Infections | 5 | 2021 | 372 | 1.110 |
Why?
| | Equipment Reuse | 2 | 2015 | 14 | 0.980 |
Why?
| | Disinfection | 2 | 2015 | 117 | 0.880 |
Why?
| | Masks | 4 | 2021 | 59 | 0.860 |
Why?
| | Microbiota | 2 | 2024 | 720 | 0.820 |
Why?
| | Antimicrobial Stewardship | 1 | 2023 | 99 | 0.730 |
Why?
| | Diabetic Foot | 1 | 2020 | 26 | 0.660 |
Why?
| | Veterans | 3 | 2020 | 1419 | 0.650 |
Why?
| | Rifampin | 1 | 2020 | 84 | 0.650 |
Why?
| | Staphylococcus aureus | 3 | 2018 | 431 | 0.600 |
Why?
| | Osteomyelitis | 1 | 2020 | 124 | 0.580 |
Why?
| | Influenza, Human | 5 | 2022 | 601 | 0.560 |
Why?
| | Sepsis | 1 | 2023 | 557 | 0.550 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 202 | 0.490 |
Why?
| | Anti-HIV Agents | 2 | 2018 | 748 | 0.470 |
Why?
| | HIV Infections | 4 | 2018 | 2710 | 0.470 |
Why?
| | Evolution, Molecular | 1 | 2018 | 467 | 0.440 |
Why?
| | Pregnancy Complications, Infectious | 7 | 2024 | 364 | 0.430 |
Why?
| | Genomics | 1 | 2018 | 716 | 0.410 |
Why?
| | Medication Adherence | 1 | 2018 | 569 | 0.410 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 1999 | 121 | 0.390 |
Why?
| | Anti-Bacterial Agents | 6 | 2024 | 1671 | 0.380 |
Why?
| | Polymers | 1 | 2015 | 473 | 0.370 |
Why?
| | Humans | 49 | 2024 | 129116 | 0.360 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 266 | 0.360 |
Why?
| | Occupational Exposure | 2 | 2019 | 311 | 0.360 |
Why?
| | Catheters, Indwelling | 1 | 2010 | 74 | 0.330 |
Why?
| | Osteoporosis | 1 | 2012 | 233 | 0.330 |
Why?
| | Catheter-Related Infections | 1 | 2010 | 68 | 0.330 |
Why?
| | Delivery of Health Care | 6 | 2022 | 894 | 0.320 |
Why?
| | Catheterization, Central Venous | 1 | 2010 | 97 | 0.310 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 106 | 0.290 |
Why?
| | Adult | 20 | 2024 | 35510 | 0.280 |
Why?
| | Influenza Vaccines | 2 | 2022 | 536 | 0.260 |
Why?
| | Female | 23 | 2024 | 68510 | 0.250 |
Why?
| | Elastomers | 2 | 2015 | 25 | 0.240 |
Why?
| | Diagnostic Imaging | 5 | 2024 | 330 | 0.240 |
Why?
| | Diverticulitis | 1 | 2024 | 8 | 0.240 |
Why?
| | Cholangitis | 1 | 2024 | 20 | 0.230 |
Why?
| | Abdominal Abscess | 1 | 2024 | 26 | 0.230 |
Why?
| | Blood Culture | 1 | 2024 | 21 | 0.230 |
Why?
| | Cholecystitis, Acute | 1 | 2024 | 23 | 0.230 |
Why?
| | Male | 20 | 2024 | 63194 | 0.230 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1999 | 222 | 0.220 |
Why?
| | Mycobacterium avium | 1 | 2004 | 22 | 0.220 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2004 | 17 | 0.220 |
Why?
| | Molecular Typing | 1 | 2013 | 19 | 0.220 |
Why?
| | Polymerase Chain Reaction | 3 | 2015 | 1021 | 0.210 |
Why?
| | Mycobacterium avium-intracellulare Infection | 2 | 2004 | 64 | 0.210 |
Why?
| | Risk Factors | 6 | 2021 | 9767 | 0.210 |
Why?
| | Middle Aged | 12 | 2020 | 31074 | 0.210 |
Why?
| | Peritonitis | 1 | 2004 | 80 | 0.210 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2013 | 66 | 0.210 |
Why?
| | Appendicitis | 1 | 2024 | 132 | 0.200 |
Why?
| | Clostridium Infections | 1 | 2023 | 56 | 0.200 |
Why?
| | Coronavirus OC43, Human | 1 | 2021 | 5 | 0.190 |
Why?
| | Pregnancy | 8 | 2024 | 6375 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2015 | 862 | 0.190 |
Why?
| | Orthomyxoviridae Infections | 1 | 2022 | 68 | 0.190 |
Why?
| | Aged | 6 | 2020 | 22083 | 0.190 |
Why?
| | Escherichia coli | 2 | 2013 | 771 | 0.180 |
Why?
| | Cohort Studies | 4 | 2020 | 5407 | 0.170 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 146 | 0.170 |
Why?
| | Viruses | 1 | 2021 | 99 | 0.170 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2019 | 17 | 0.160 |
Why?
| | United States | 9 | 2024 | 13938 | 0.160 |
Why?
| | Placebos | 1 | 2020 | 201 | 0.160 |
Why?
| | Attitude | 1 | 2021 | 250 | 0.160 |
Why?
| | Hepatitis B, Chronic | 1 | 1999 | 18 | 0.160 |
Why?
| | Lamivudine | 1 | 1999 | 61 | 0.160 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 95 | 0.160 |
Why?
| | Retrospective Studies | 7 | 2020 | 14571 | 0.160 |
Why?
| | Aged, 80 and over | 3 | 2020 | 7064 | 0.160 |
Why?
| | Financing, Government | 1 | 1999 | 42 | 0.150 |
Why?
| | Risk Assessment | 4 | 2024 | 3260 | 0.150 |
Why?
| | Foot | 1 | 2020 | 123 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2020 | 220 | 0.150 |
Why?
| | Hospitalization | 3 | 2018 | 2077 | 0.150 |
Why?
| | Mandatory Programs | 1 | 2018 | 14 | 0.150 |
Why?
| | Outpatients | 1 | 2021 | 367 | 0.150 |
Why?
| | Sterilization | 1 | 2017 | 11 | 0.140 |
Why?
| | Vaccination Coverage | 1 | 2018 | 80 | 0.140 |
Why?
| | Herpes Zoster Vaccine | 1 | 2018 | 162 | 0.130 |
Why?
| | Antibiosis | 1 | 2015 | 9 | 0.130 |
Why?
| | Streptococcus mitis | 1 | 2015 | 9 | 0.130 |
Why?
| | Lactobacillus | 1 | 2015 | 26 | 0.130 |
Why?
| | Vaccination | 3 | 2021 | 1349 | 0.120 |
Why?
| | Catalase | 1 | 2015 | 122 | 0.120 |
Why?
| | Nasal Mucosa | 1 | 2016 | 107 | 0.120 |
Why?
| | Pyrimethamine | 1 | 1995 | 1 | 0.120 |
Why?
| | Sulfadoxine | 1 | 1995 | 4 | 0.120 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 147 | 0.120 |
Why?
| | Disease Transmission, Infectious | 1 | 2015 | 57 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2020 | 1865 | 0.120 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1995 | 33 | 0.120 |
Why?
| | Equipment Contamination | 1 | 2015 | 57 | 0.120 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 773 | 0.120 |
Why?
| | Child | 9 | 2024 | 20805 | 0.120 |
Why?
| | Reference Standards | 1 | 2015 | 170 | 0.120 |
Why?
| | Efficiency, Organizational | 2 | 2018 | 134 | 0.110 |
Why?
| | Occupational Diseases | 1 | 2016 | 141 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2020 | 10226 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 582 | 0.110 |
Why?
| | Herpes Zoster | 1 | 2018 | 317 | 0.110 |
Why?
| | Hospitals, Veterans | 1 | 2015 | 257 | 0.110 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 173 | 0.110 |
Why?
| | Medical Errors | 1 | 2015 | 104 | 0.110 |
Why?
| | Virus Diseases | 1 | 2016 | 209 | 0.110 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4915 | 0.110 |
Why?
| | Prospective Studies | 3 | 2020 | 7079 | 0.110 |
Why?
| | Mycobacterium Infections | 1 | 1993 | 62 | 0.100 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 521 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 864 | 0.100 |
Why?
| | HIV-1 | 1 | 1999 | 842 | 0.100 |
Why?
| | Intensive Care Units | 2 | 2015 | 719 | 0.100 |
Why?
| | Bone Density Conservation Agents | 1 | 2012 | 73 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1210 | 0.100 |
Why?
| | Prevalence | 2 | 2013 | 2564 | 0.100 |
Why?
| | Biomarkers | 1 | 2023 | 3896 | 0.100 |
Why?
| | Osteoporotic Fractures | 1 | 2012 | 57 | 0.090 |
Why?
| | Acute Disease | 2 | 2024 | 968 | 0.090 |
Why?
| | Incidence | 2 | 2019 | 2635 | 0.090 |
Why?
| | United States Department of Veterans Affairs | 1 | 2015 | 637 | 0.090 |
Why?
| | Ergonomics | 1 | 2010 | 23 | 0.090 |
Why?
| | Longitudinal Studies | 2 | 2015 | 2715 | 0.090 |
Why?
| | Listeria monocytogenes | 1 | 1990 | 123 | 0.080 |
Why?
| | Metagenome | 1 | 2010 | 137 | 0.080 |
Why?
| | Colorado | 2 | 2018 | 4394 | 0.080 |
Why?
| | Molecular Epidemiology | 2 | 2013 | 63 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 1013 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2739 | 0.060 |
Why?
| | Cytosine | 1 | 2005 | 46 | 0.060 |
Why?
| | Organophosphonates | 1 | 2005 | 91 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2005 | 93 | 0.060 |
Why?
| | Ambulatory Care | 2 | 2019 | 506 | 0.060 |
Why?
| | Immunocompetence | 1 | 2004 | 43 | 0.060 |
Why?
| | Adolescent | 3 | 2020 | 20301 | 0.050 |
Why?
| | Fluoroquinolones | 1 | 2013 | 37 | 0.050 |
Why?
| | beta-Lactams | 1 | 2013 | 26 | 0.050 |
Why?
| | Young Adult | 1 | 2020 | 12389 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 385 | 0.050 |
Why?
| | Inpatients | 2 | 2020 | 464 | 0.050 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2022 | 38 | 0.050 |
Why?
| | Virulence Factors | 1 | 2013 | 153 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2022 | 43 | 0.050 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 177 | 0.050 |
Why?
| | Nurses | 1 | 2023 | 164 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2023 | 715 | 0.040 |
Why?
| | Hepatitis B e Antigens | 1 | 1999 | 2 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2005 | 706 | 0.040 |
Why?
| | Program Evaluation | 2 | 2015 | 876 | 0.040 |
Why?
| | Drug Resistance | 1 | 1999 | 163 | 0.040 |
Why?
| | Genotype | 1 | 2013 | 1832 | 0.040 |
Why?
| | Treatment Failure | 1 | 1999 | 343 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 603 | 0.040 |
Why?
| | Absenteeism | 1 | 2018 | 49 | 0.040 |
Why?
| | Surgical Instruments | 1 | 2017 | 53 | 0.030 |
Why?
| | Hospital Costs | 1 | 2017 | 117 | 0.030 |
Why?
| | Immunization Programs | 1 | 2018 | 212 | 0.030 |
Why?
| | Recurrence | 1 | 1999 | 1003 | 0.030 |
Why?
| | Hand Hygiene | 1 | 2015 | 8 | 0.030 |
Why?
| | Operating Rooms | 1 | 2017 | 115 | 0.030 |
Why?
| | Pentamidine | 1 | 1995 | 4 | 0.030 |
Why?
| | Seasons | 1 | 2018 | 498 | 0.030 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 30 | 0.030 |
Why?
| | Personal Protective Equipment | 1 | 2015 | 51 | 0.030 |
Why?
| | Zidovudine | 1 | 1995 | 77 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 353 | 0.030 |
Why?
| | Workplace | 1 | 2016 | 249 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 1995 | 664 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 328 | 0.030 |
Why?
| | Occupational Health | 1 | 2015 | 196 | 0.030 |
Why?
| | Digestive System | 1 | 1991 | 30 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2015 | 464 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2018 | 897 | 0.020 |
Why?
| | Listeria | 1 | 1990 | 6 | 0.020 |
Why?
| | Patients' Rooms | 1 | 2010 | 13 | 0.020 |
Why?
| | Facility Design and Construction | 1 | 2010 | 12 | 0.020 |
Why?
| | Manikins | 1 | 2010 | 23 | 0.020 |
Why?
| | Diarrhea | 1 | 1991 | 177 | 0.020 |
Why?
| | Time and Motion Studies | 1 | 2010 | 21 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1990 | 172 | 0.020 |
Why?
| | Hand Disinfection | 1 | 2010 | 23 | 0.020 |
Why?
| | Bacterial Typing Techniques | 1 | 2010 | 42 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2010 | 82 | 0.020 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 116 | 0.020 |
Why?
| | Quality Control | 1 | 2010 | 156 | 0.020 |
Why?
| | Health | 1 | 2010 | 74 | 0.020 |
Why?
| | Feedback | 1 | 2010 | 159 | 0.020 |
Why?
| | Staphylococcus epidermidis | 1 | 2010 | 75 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 6518 | 0.020 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1995 | 378 | 0.020 |
Why?
| | Checklist | 1 | 2010 | 96 | 0.020 |
Why?
| | Species Specificity | 1 | 1990 | 570 | 0.020 |
Why?
| | Problem Solving | 1 | 2010 | 156 | 0.020 |
Why?
| | Workload | 1 | 2010 | 152 | 0.020 |
Why?
| | Equipment Design | 1 | 2010 | 518 | 0.020 |
Why?
| | Cues | 1 | 2010 | 321 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 324 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 324 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 152 | 0.020 |
Why?
| | Attention | 1 | 2010 | 437 | 0.020 |
Why?
| | Biodiversity | 1 | 2010 | 373 | 0.020 |
Why?
| | Motivation | 1 | 2010 | 545 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1990 | 1825 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2819 | 0.020 |
Why?
| | Simplexvirus | 1 | 2005 | 80 | 0.010 |
Why?
| | Drug Resistance, Viral | 1 | 2005 | 111 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 268 | 0.010 |
Why?
| | Bacteria | 1 | 1990 | 811 | 0.010 |
Why?
| | Life Tables | 1 | 1995 | 18 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 267 | 0.010 |
Why?
| | Mycobacterium avium Complex | 1 | 1995 | 90 | 0.010 |
Why?
| | Australia | 1 | 1995 | 246 | 0.010 |
Why?
| | Europe | 1 | 1995 | 362 | 0.010 |
Why?
| | North America | 1 | 1995 | 289 | 0.010 |
Why?
| | Survival Rate | 1 | 1995 | 1875 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1995 | 3342 | 0.000 |
Why?
|
|
Bessesen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|